Conjugated estrogens
Conjugated estrogens (CEE) are a mixture of naturally derived estrogen compounds used in oral hormone therapy, most commonly as brand Premarin.
How it works
Conjugated estrogens contain a mixture of estrogen sulfates — primarily estrone sulfate, equilin sulfate, and 17α-dihydroequilin — rather than the pure estradiol used in bioidentical hormone therapy. The Women's Health Initiative used conjugated equine estrogens (CEE, Premarin) in its landmark trials. Like all oral estrogens, CEE undergoes first-pass liver metabolism, which stimulates hepatic production of clotting factors and sex hormone-binding globulin more than transdermal estradiol does. This distinction matters for risk profile assessment, particularly in women with elevated cardiovascular or clotting risk.
CEE is effective for treating vasomotor symptoms, bone loss, and genitourinary atrophy. For women with a uterus, a progestogen must be added. The combination of Premarin plus medroxyprogesterone (Prempro) was the formulation studied in the WHI trial that raised concerns about combined HRT risk — subsequent analyses have distinguished the risks associated specifically with that combination and that patient population from the broader question of HRT safety.
How to track Conjugated estrogens
- Hot flash frequency and severity — the primary vasomotor response measure.
- Breakthrough bleeding or spotting if on a combined regimen — log with dates and description.
- Sleep quality and night sweats as secondary vasomotor response indicators.
- Nausea — more common with oral than transdermal estrogen, particularly in early weeks.
- Breast tenderness and bloating — dose-overshoot signals applicable to all oral estrogens.
- Establish a hot flash baseline before starting — CEE is effective for vasomotor symptoms, and your log shows the response trajectory.
- Log nausea in the first two to four weeks separately from other side effects — it is common with oral estrogen and often resolves as the body adjusts.
- Log breakthrough bleeding with dates and description — this is the most important monitoring variable on any combined estrogen-progestogen regimen.
- Track breast tenderness and bloating carefully alongside dose information — these are dose-overshoot signals that can guide dose adjustments.
- Note the date of any dose changes so pre- and post-adjustment windows can be compared cleanly.
Questions to ask your physician
- My pre-treatment hot flash baseline was [X] per day. At [N] weeks on conjugated estrogens, my current average is [Y]. Is that response at the expected level?
- Given my personal risk profile, is the oral CEE route still preferred, or should we discuss transdermal estradiol options?
- I've been logging breakthrough bleeding on [dates, description] — what does that pattern suggest?
- My breast tenderness log shows [pattern] — does that suggest my dose is higher than the minimum effective level?